Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


3SBio Acquires Wansheng To Bolster Small Molecule Portfolio

This article was originally published in PharmAsia News

Executive Summary

China’s 3SBio has been actively scouting M&A targets in both overseas and domestic markets, aiming to enrich its product pipeline and diversify its offering. It has now landed its first acquisition, of a chemical drug maker in China, just one month after its Hong Kong IPO, in a deal that will provide 3SBio with an integrated small molecule R&D and manufacturing platform and increase its manufacturing cost competitiveness.



Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts